Novanta Inc. (0VAG)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 134.85 |
|---|---|
| 52-week range | 99.31 – 176.49 |
| Return, 1 month / 3 months | −6.3% / −7.2% |
| Return, 1 year / 3 years | +14.5% / −4.1% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 48.7% |
| Worst drawdown (1 year) | -25.1% |
| Average daily value traded | 0.07M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novanta Inc. supplies precision components and subsystems used in medical equipment and advanced industrial systems. Its products include laser scanning and photonics devices, machine vision and encoder components, and specialized lighting and motion control parts. Customers are original equipment manufacturers in healthcare, life sciences and automation, who build these parts into their own instruments and machines. The company is based in Bedford, Massachusetts, in the United States, and serves customers in markets around the world.
On this site Novanta Inc. appears as a stock on the London Exchange (UK), code 0VAG, with prices in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novanta Inc. (0VAG) trades on the London Exchange in UK. It last closed at USD 134.85 on 22 October 2026.
Its price-based Market X-Ray is 43 out of 100 (a weak price profile), ranking 2,434 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.5% and over the last three months it fell 7.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 44 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.3% | ||
| From 52-week high | -20.6% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -7.2% | ||
| 6-month return | 1.0% | ||
| 12-month return, skipping the last month | 22.2% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.1% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | −6.3% |
| 3 months | −7.2% |
| 6 months | +1.0% |
| 1 year | +14.5% |
| 3 years | −4.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 144.01 / 142.40 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.81 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.